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Abstract
Background and Objective: Cardiovascular Diseases (CVDs) are the 
leading non-communicable diseases and also leading cause of morbidity and 
mortality worldwide. Low Molecular Weight Heparin (LMWHs) is frequently 
prescribed medication in CVDs. Prescribing pattern of LMWHs in CVDs is 
necessary to recommends modifications to achieve rational and cost-effective 
medical care. 
Methodology: An inpatients hospital based observational prospective 
study for a period of six months was carried out. Data was collected from 
patient medication sheet and analyzed by suitable methods and standard 
references.
Results and Discussion: In our study, a total of 120 patients were enrolled 
out of 120 patients 84 were male and 36 were female. Antiplatelet drug is 
maximum prescribing drug in 98 (81.34%) patients out of 120, then after 
hypolipidaemic drugs in 94 (78.02%), Anticoagulant in 92 (76.36%), 
Antibiotics in 90 (74.70%), Antianginal in 69 (57.27), Antihypertensive in 
64 (53.12%), Diuretics in 59 (48.97%). LMWHs are prescribed in 78 (65%) 
in which Enoxaparin is prescribed in 67(55%) and Dalteparin in 11(10%) 
patients out of 120 patients. Total 259 Drug-Drug Interactions (DDI) were 







Conclusion: The study show LMWHs are highly prescribed category of 
anticoagulant. Enoxaparin is prescribed morethan Dalteparin. Antiplatelet 
drugs are prescribed to every patient who is prescribed with LMWHs to prevent 
embolic event. Chance of DDI is increases with these combinations. LMWHs 
and Fibrinolytic drugs are very costly and impart maximum economic burden 
to middle class family.
Keywords: Cardiovascular diseases, Drug- Drug Interactions, Heparin, Low 
Molecular Weight Heparin.
1. INTRODUCTION
Cardiovascular diseases (CVDs) are related with heart and blood vessels& 
specially included coronary artery diseases (CAD), pulmonary embolism 
(PE) and deep vein thrombosis (DVT), congenital heart diseases & rheumatic 
heart diseases. People died from CVDs in 2008 were 17.3 million (30% of 
all global deaths). Out of 17.3 million CVDs global mortality, 7.3 million 
were by coronary heart diseases and 6.2 million by stroke (WHO Fact sheet, 
2011). Similarly in Indian scenario cardiovascular mortality was one-fourth of 
all mortality in 2008. With 9.2 % annual growth CVDs were fastest-growing 
chronic illness between 2005 and 2015(Chauhan et al., 2001; Cardiovascular 
Diseases in India 2010). Cardiovascular diseases include Coronary artery 
disease, deep vein thrombosis, and pulmonary embolism. Coronary artery 
disease (CAD) can classify into Ischemic Heart Disease (IHD) and Acute 
Coronary Syndrome (ACS). IHD is chiefly caused by the formation of coronary 
atherosclerotic plaque that creates an imbalance between oxygen supply 
and demand resulting ischemia in the myocardium. While ACS is a clinical 
condition when an atherosclerotic plaque get ruptured with following platelet 
adherence, activation, aggregation, and clotting cascade that eventually leads a 
clot formed by fibrin and platelets (Enas et al., 2007). Blockage of the main artery 
or one of its branches of lungs by an embolus that has traveled from elsewhere 
in the body through the blood stream is called pulmonary embolism (Balady 
et al., 2007). Formation of thrombus within a deep vein chiefly in the legs is 
called Deep vein thrombosis (DVT) (Dipiro, 2008). Drugs categories such 
as antiplatelet, anticoagulants, beta blockers, angiotensin-converting enzyme 
inhibitor (ACEI) / Angiotensin II receptor blockers (ARBs), calcium channel 
blockers (CCBs), diuretics, and statins are involved in the treatment of CAD, 
DVT, and PE. In high- income countries drug utilization strategies for CAD is 
well established but in India, these strategies have not been fully implemented 
(Goldhaber et al., 2005). The study of prescribing habits is a part of the medical 
assessment that involves monitoring and assessment of the prescribers as well 
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as suggests necessary alterations in drug therapy achieve rational, cogent, and 
cost-beneficial care. Studies of prescribing habits in CVD patients are useful 
to identify the harms and provide feedback to prescribers for awareness about 
rational drug use (Srishyla et al., 1994). Therefore, this study was able to 
analyze the current prescription pattern of LMWHs with cardiovascular drugs 
that prescribed during the study and Drug-Drug Interactions between these 
drugs. The study also analyzes cost of CVDs and explore economic burden 
on patients. 
2. METHODOLOGY 
A prospective observational study was carried out in a tertiary care hospital 
over the duration of 6 months from December 2013 to June 2014. The 
study was approved by the ethical committee vide approval letter number 
IECBLDECOP/2014/06.
2.1 Study Criteria
The patients admitted to intensive care unit of the department by considering 
following criterion.
2.2 Inclusion criteria
All patients diagnosed with CVDs (Ischemic Heart disease, acute coronary 
syndrome (ACS), Deep vein thrombosis (DVT), and Pulmonary embolism 
(PE), of either sex and are more than 18 years admitted to the intensive care 
unit were included.
2.3 Exclusion criteria
In patients diagnosed other than CVDs and all Inpatients admitted other than 
ICU, ICCU, and New Emergency Wards.
3. DATA COLLECTION
Data was collected on data collection format from the patients who came under 
inclusion criteria. Patient demographic detail (age, sex), diagnosis, laboratory 
investigations, and advised medications were noted down on data collection 
format from the medical records.
To study the drug prescribing habits in cardiovascular disease, all patients 
diagnosed with coronary artery disease, Deep vein thrombosis, and pulmonary 
embolism were included in the study for analysis. The trade names of drugs 







clopidogrel used as antiplatelet agents; beta-blockers (BB), Angiotensin-
Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers 
(ARBs), and calcium channel blockers (CCBs) used as antihypertensive 
agents; HMG-CoA reductase (Statins), and fenofibrate used as lipid-
lowering medicines; Nitrates, potassium channel openers (e.g. Nicorandil) 
used as antianginal drugs for chest pain; Unfractionated heparin (UFH) and 
Low Molecular Weight Heparin (LMWHs) were used as anticoagulants; 
streptokinase used as fibrinolytic. Other classes of drugs such as diuretics, 
bronchodilators, antibiotics, multivitamins, anti-diabetic medications were 
also included. Analysis of utilization of different classes of drugs as well as 
individual drugs was evaluated and depicted as the percentage.
4. RESULTS
During the entire study period, 120 patients were enrolled. Out of 120 patients, 
84 were male and 36 were female. The male to female ratio among the patients 
was 7:3. The average age for all enrolled patient was 68.16 ± 4.49.
Aging increases chance of cardiovascular morbidity. In present study 
maximum, 72 (60%) enrollment occurred in the age group between 60 to 80 
years. Various age wise distribution of CVD patients are shown in Table 1.
During whole study diagnosed patients were categorized into ischemic 
heart disease (IHD), acute coronary syndrome (ACS), pulmonary embolism 
(PE), and deep vein thrombosis (DVT). During study period maximum 76 
(63.80 %) had ischemic heart disease (IHD), then 38 (31.54%) ACS was 
diagnosed.
The risk of cardiovascular diseases in patients who have whether 
prehypertension or hypertension is very high. Hence in present study 
depicted that highest comorbid condition is Hypertension and then on the 
second position were diabetes Various Co-morbid conditions are described 
in Table 2.
Table 1: Age distribution of patients.
S. No. Age group (years) No of patients (n=120) Percent (%)
1. 20-39 08 6.7
2. 40-59 34 28.3
3. 60-80 72 60
4. >80 06 5
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Acute Coronary Syndrome (ACS), Deep Vein Thrombosis (DVT), 
Diabetes Mellitus (DM), Hypertension (HTN), Ischemic Heart Disease (IHD), 
Left Ventricular Failure (LVF), Mitral Regurgitation (MR)
The treatment of cardiovascular diseases involves different categories of 
drugs such as antiplatelet drug, anticoagulant, fibrinolytics, anti-anginal drugs, 
antihypertensive, antihypertensive, antihyperlipidemic agent, bronchodilators, 
and antibiotics. Details of different categories of prescribed drugs are given in 
table 3.
Table 2: Co-morbid conditions with cardiovascular disease.
S. No. Co-morbid conditions No. of patients (n=120) Percent (%)
1. IHD 18 15
2. ACS+IHD 10 8.3
3. ACS 14 11.7
4. IHD+HTN 8 6.7
5. IHD+Type2 DM 15 12.5
6. IHD+LVF 5 4.2
7. IHD+CHF 6 5
8. IHD+HTN+Type2 DM 18 15
9. ACS+LVF+IHD 1 0.8
10. ACS+HTN 2 1.7
11. IHD+CHF+ Type2 DM 2 1.7
12. IHD+MR 4 3.3
13. ACS+DM Type2 9 7.5
14. ACS+LVF 2 1.7
15. PE+HTN 3 2.5
16. DVT 3 2.5







Out of 120 patients, 15 patients were thrombolized with streptokinase for 
dissolving fibrin clots and for preventing re-occlusion anticoagulants are 
prescribed in which LMWHs are prescribed in 78 patients and 9 patients with 
Unfractionated heparin. Details of prescribed anticoagulants are shown in 
Table 4.
Table 3: Different Categories of Drugs Prescribed to the 120 Patients.
S.N. Drug Categories No. of Patients out of 120 % of patients
1. Antiplatelet 98 81.34
2. Hypolipidaemic Drug 94 78.02
3. Antibiotics 90 74.70
4. Antianginal 69 57.27
5. Anti HTN 64 53.12
6. Anti coagulant 92 76.36
7. Diuretics 59 48.97
8. Bronchodilators 45 37.35
9. Antacids 98 81.34
10. OHA 46 38.18
11. NSAIDs 48 39.84
Table 4: Description of LMWHs prescribed to the Patients.
S. No. Drug No. of Patients out of 120
% out of 120 
patient
1. Enoxaparin Sod. 67 56
2. Dalteparin sod. 11 9
3. Heparin 9 7
4. Patient without anticoagulation therapy 36 30
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During the whole study period total of 259 DDIs were reported out of which 
140 is moderate type of DDIs were predominant. The moderate drug-drug 
interactions were mainly occurred in between antiplatelet and low molecular 
weight heparin (LMWHs) in 78 (76%) patients. The major DDIs between 
antiplatelet and heparin was found in 9 (7.5%) and moderate DDIs between 
aspirin and Streptokinase was found in 15 patients. DDIs between antiplatelet, 
low molecular weight heparins, unfractionated heparin and streptokinase can 
cause potential bleeding. 
5. DISCUSSION 
The present study showed the utilization pattern of LMWHs. Clinical 
importance of LMWHs was showed in the meta-analysis of more than 7500 
patients that states LMWHs reduce mortality and chance of reinfarction 
compared to placebo (Eikelboom, 2005). On comparing with unfractionated 
Table 5: Detail of antiplatelet drug andLMWHs with various categories.
S. No. Drug prescribed with 
LMWHs
No. of Patients 
out of 120
Percentage out of 
120 patient
1. LMWH + Antiplatelet 78 65
2. LMWH + Antiplatelet + 
Antihypertensive
73 61
3. LMWH + Antiplatelet + 
Anti-acid drugs
98 81
4. LMWH + Antiplatelet + 
Hypolipidaemic
78 65
5. LMWH + Antiplatelet + 
Antibiotics
60 50
Table 6: Details of different DDIs occur in Patients.











heparin, chances of reinfarction are more if UFH is not given in combination 
with fibrin-selective agents like alteplase, reteplase, and tenecteplase (Gruppo, 
1990).  These fibrin selective agents are very costly approximately 19800 
INR in India (Alteplase, 2017) while non-fibrin selective agent streptokinase 
(STK) is 1900 INR (Streptokinase, 2017). Due to the affordable cost of 
streptokinase, it is used frequently in India. Use of UFH with STK has no 
benefit (Gruppo, 1990). In such situation, LMWHs are the drug of choice 
after thrombolysis with STK. By this study importance of LMWHs is shown, 
it is prescribed in 68% of patients and also suggest for the reduction of prices 
in fibrin selective agents. Cardiovascular illness causes nearly 2400 deaths 
in Americans every day, or an average of 1 mortality in every 33 seconds. 
Morality by coronary artery disease impacts 52% of deaths out of total 
cardiovascular mortality. Mortality in men become earlier from coronary 
artery diseases than women, and aging leads higher mortality in both sexes 
(Dipiro, 2008). In a retrospective study conducted on the 140 patients, out of 
them 96 patients were male and 44 of them were female with an average age of 
62 years (Range 36-83 years) and 61 years (Range 30-80 years) respectively 
(Sandozi & Nausheen, 2010). In the present study Out of 120 patients, 84 
were male and 36 were female. The male to female ratio among the patients 
was 7:3. The present study also showed consistency results with previous 
studies that male were more prone to coronary artery disease compared to 
female and the risk is increased with increasing age. Treatment Goals for 
cardiovascular diseases includes early re-establishment of blood flow to the 
infarct-related artery to prevent infarct development (in the case of MI) or 
prevent complete occlusion and MI (in unstable angina), relief of ischemic 
chest discomfort, prevention of coronary artery re-occlusion, and prevention 
of mortality and other complications (Dipiro, 2008). 
Antiplatelet and anticoagulant are indicated for the prevention of further re-
occlusion. Aspirin has become preferred antiplatelet agent for ACS (Antman, 
2004) and administration of aspirin within first 24 hours of hospitalization is 
an indicator of good quality care (Krumholz, 2006). Aspirin inhibits platelet 
cyclooxygease-1 (Cox-1) irreversibly by which synthesis of thromboxane A2 
is inhibited. Administration of its non-enteric-coated formulation rapidly (<10 
minutes) inhibits thromboxane A2 production in the platelets. Aspirin also 
reduces C-reactive protein that showed its effectiveness in ACS (Krumholz, 
2006).The study conducted by Muntwyler, et al., showed high prescription 
rate for antithrombotic agents (90%), then beta blockers, ACEI/ARBs, and 
lipid-lowering agents were 58%, 50% and 63% respectively (Muntwyler et al., 
2003).In our study antithrombotic agents, antihypertensive agents and lipid-
lowering agents were 81.34, 53.12 and 78.02 respectively. In our study, we 
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found every patient were prescribed with aspirin that was quality care indicator 
for all coronary heart diseases. 
Administration of anticoagulant, unfractionated heparin (UFH) involves 
two steps first as an IV bolus and second is a continuous infusion that is a 
first-line anticoagulant treatment for the patients of ST-elevated ACS, and 
for patients undergoing percutaneous interventions (PCI) (Levine, 2006). 
Mechanism of action of UFH is to bind with antithrombin and then inhibits 
the function of clotting factors Xa and IIa (thrombin) while LMWHs also 
bind to antithrombin but due to their short saccharide chain lengths, they 
preferentially inhibit factor Xa over IIa, which is required larger chain lengths 
for binding and inhibition.  On comparing adverse effects (ADRs) of these two 
UFH and LMWHs, the UFH has most frequent ADR that is thrombocytopenia 
and bleeding, which frequency is up to 5% of patients treated with UFH while 
thrombocytopenia is less common in patients on LMWHs (Antman, 2004; 
Levine, 2006).
Relative benefits between LMWHs and UFH is recently compared in a 
trial Thrombolysis in Myocardial Infarction (TIMI) that stated enoxaparin 
significantly reduced the risk of mortality or nonfatal MI compared to UFH 
administered patients (Dipiro, 2008). In present study showed that utilization 
of UFH was only in 7.47 percent patients while LMWHs was 78% that support 
result of large TIMI trial by more utilization of LMWHs while study conducted 
by Sandozi et al. showed prescription rates for Unfractionated heparin is 
more (55.71%) in compare to Low molecular weight heparin (20.00%) 
(Sandozi, 2010).
6. CONCLUSION
The study shows that LMWHs are the highly prescribed category of 
anticoagulants for cardiovascular diseases. Hypertension and diabetes were 
the highly diagnosed co-morbid conditions associated with coronary artery 
disease. Enoxaparin is administered in more patients than Dalteparin. 
Antiplatelet drugs are prescribed to every patient who is prescribed LMWHs 
to prevent an embolic event. Polypharmacy was noticed in almost every 
prescription. The rational drug prescription can be improved simultaneously 
chance of DDI can be reduced by minimizing polypharmacy. LMWHs and 
fibrinolytic drugs are very costly and impart maximum economic burden to 
the middle class family. 
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